- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Pricing
- SKY Learn
- Mutual Funds
- Margin Trading
- Financial Planning
- Personal Finance
- Share Trading
- IPO
- Derivatives
- Currencies
- Intraday Trading
- Trading Strategies
- Demat Account
- Commodity
- ETF
Curis Lifesciences IPO
₹1,20,000/1000 shares
Minimum Investment
IPO Details
07 Nov 25
11 Nov 25
₹1,20,000
1000
₹120 to ₹128
NSE
₹27.52 Cr
14 Nov 25
Curis Lifesciences IPO Timeline
Bidding Start
07 Nov 25
Bidding Ends
11 Nov 25
Allotment Finalisation
12 Nov 25
Refund Initiation
13 Nov 25
Demat Transfer
13 Nov 25
Listing
14 Nov 25
Curis Lifesciences Limited
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of pharmaceutical products. The company operates both globally and domestically on a loan licence or contract manufacturing basis, along with its own brand marketing. It caters to over 100 corporate clients and serves two international clients in Yemen and Kenya. Its product portfolio includes tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments, manufactured at its advanced Sanand, Gujarat facility.
Curis Lifesciences Limited IPO Overview
Curis Lifesciences Limited IPO is a book-built issue valued at ₹27.52 crore, comprising an entirely fresh issue of 0.22 crore equity shares. The IPO will open for subscription on 7 November 2025 and close on 11 November 2025. The basis of allotment is expected to be finalised on 12 November 2025, while the company’s shares are proposed to be listed on the NSE SME platform with a tentative listing date of 14 November 2025.
The price band for the issue has been set between ₹120 and ₹128 per share, and the lot size is 1,000 shares. The minimum investment required for retail investors is ₹2,56,000 (based on the upper price band), while High Net-worth Individuals (HNIs) can apply for a minimum of three lots (3,000 shares), amounting to ₹3,84,000.
Finaax Capital Advisors Private Limited is the Book Running Lead Manager of the issue, and MUFG Intime India Private Limited serves as the Registrar. The Market Maker for the Curis Lifesciences IPO is RS Wealth Management Private Limited.
Curis Lifesciences Limited IPO Details
| Particulars | Details |
| IPO Date | 7 November 2025 to 11 November 2025 |
| Listing Date | 14 November 2025 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹120 to ₹128 per share |
| Lot Size | 1,000 Shares |
| Total Issue Size | 21,50,000 shares (aggregating up to ₹27.52 Crore) |
| Fresh Issue | 21,50,000 shares (aggregating up to ₹27.52 Crore) |
| Offer for Sale | NA |
| Issue Type | Book-building IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 59,34,434 shares (≈92.68%) |
| Share Holding Post Issue | 80,84,434 shares (≈68.03%) |
| Market Maker Portion | 1,08,000 shares |
Curis Lifesciences Limited IPO Reservation
| Investor Category | Shares Offered |
| Market Maker | 1,08,000 (≈5.02%) |
| QIB | 10,18,000 (≈47.35%) |
| NII (HNI) | 3,08,000 (≈14.33%) |
| Retail | 7,16,000 (≈33.30%) |
| Total Shares Offered | 21,50,000 (100%) |
Curis Lifesciences Limited IPO Lot Size
| Application | Lots | Shares | Amount |
| Retail (Min) | 2 | 2,000 | ₹2,56,000 |
| Retail (Max) | 2 | 2,000 | ₹2,56,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,84,000 |
| S-HNI (Max) | 7 | 7,000 | ₹8,96,000 |
Curis Lifesciences Limited IPO Promoter Holding
| Shareholding Status | Percentage |
| Pre-Issue | 92.68% |
| Post-Issue | 68.03% |
Curis Lifesciences Limited IPO Valuation Overview
| KPI | Value |
| Earnings Per Share (EPS) | ₹10.29 |
| Price/Earnings (P/E) | ~12.44× |
| Return on Net Worth (RoNW) | 37.62% |
| Net Asset Value (NAV) | ₹27.34 per share |
| Return on Equity (ROE) | 55.25% |
| Return on Capital Employed (ROCE) | 27.83% |
| EBITDA Margin | 19.41% |
| PAT Margin | 12.43% |
| Debt to Equity Ratio | 0.96 |
Objectives of the Proceeds
- Capital expenditure towards up-gradation of manufacturing facilities: ₹2.44 Cr
- Capital expenditure towards construction of storage facility: ₹3.62 Cr
- Pre-payment/repayment of outstanding secured loans: ₹1.86 Cr
- Product registrations in other countries: ₹2.69 Cr
- Funding working capital requirements: ₹11.25 Cr
- General corporate purposes: amount unspecified
Key Financials (in ₹ crore)
| Particulars | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 56.29 | 42.53 | 33.88 | 29.75 |
| Total Income | 19.51 | 49.65 | 35.87 | 36.42 |
| Profit After Tax (PAT) | 2.87 | 6.11 | 4.87 | 1.88 |
| Reserves and Surplus | 13.16 | 10.29 | 5.37 | 0.51 |
| Total Borrowings | 15.32 | 15.62 | 17.09 | 16.19 |
SWOT Analysis of Curis Lifesciences IPO
Strength and Opportunities
- Promoters and management team possess extensive experience and technical expertise.
- Well-established presence in domestic and international markets.
- Maintains long-term client relationships with consistent repeat business.
- Strong and reliable supplier network supporting operations.
- Large, integrated manufacturing facility strategically located for operational efficiency.
- Adheres to quality standards with recognized certifications and accreditations.
Risks and Threats
- Manufacturing concentrated in one location may pose operational risk.
- Highly competitive pharmaceutical industry with margin pressure.
- Exposure to loan-license/contract manufacturing may reduce control over branding.
- Regulatory/regulatory change risks in export and own-brand markets.
- Dependence on a limited number of large clients could pose concentration risk.
- Business depends on regulatory approvals and faces potential delays.
Explore IPO Opportunities
Explore our comprehensive IPO pages to stay updated on the latest trends and insights.
About Curis Lifesciences Limited
Curis Lifesciences IPO Strengths
- Promoters and management team possess extensive experience and technical expertise.
- Well-established presence in both domestic and export markets.
- Long-term relationships with clients and consistent repeat business.
- Integrated manufacturing facility with strong supply chain support.
- Adheres to global quality standards and certifications.
- Focus on continuous research, innovation, and product diversification.
Peer Group Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (₹ per share) | P/E (x) | RoNW (%) | P/BV Ratio |
| Curis Lifesciences Limited | 10.29 | 10.29 | 27.34 | — | 37.62 | — |
| Peer Group | ||||||
| Sotac Pharmaceuticals Limited | 4.32 | 4.32 | 47.99 | 18.30 | 9.00 | 2.72 |
| Lincoln Pharmaceuticals Limited | 41.11 | 41.11 | 335.34 | 12.21 | 12.27 | 1.58 |
How to apply IPO with HDFC SKY?
Follow these simple steps to apply for an IPO through HDFC SKY. Secure your investments and explore new opportunities with ease by accessing the IPOs available on the platform.
1Login to your HDFC SKY Account
2Select Issue
3Enter Number of Lots and your Price.
4Enter UPI ID
5Complete Transaction on Your UPI App
FAQs On Curis Lifesciences IPO
How can I apply for Curis Lifesciences IPO?
You can apply via HDFCSky using UPI-based ASBA during the subscription window.
What is the minimum investment required for the Curis Lifesciences IPO?
Minimum investment is ₹2,56,000 for 2,000 shares at the upper price band.
Which exchange will the Curis Lifesciences IPO list on?
The IPO will list on the NSE SME platform (NSE EMERGE).
What is the price band and lot size for the Curis Lifesciences IPO
The price band is ₹120-₹128 per share and the lot size is 1,000 shares.
By signing up I certify terms, conditions & privacy policy